In one paragraphArticle in JMIR research protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
23 authors.
Qingyu Xie *The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, No. 42, Baiziting, Nanjing, 210009, China, 86 13776689750.ORCID 0009-0008-4296-4584 Rui Peng *The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, No. 42, Baiziting, Nanjing, 210009, China, 86 13776689750.ORCID 0000-0003-1551-9334 Chao Yue *The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, No. 42, Baiziting, Nanjing, 210009, China, 86 13776689750.ORCID 0000-0001-9952-0791 Wei Wei *The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, No. 42, Baiziting, Nanjing, 210009, China, 86 13776689750.ORCID 0000-0003-4184-267X Lingli Huang *The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, No. 42, Baiziting, Nanjing, 210009, China, 86 13776689750.ORCID 0000-0002-6686-5942 Haitian WangThe Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, No. 42, Baiziting, Nanjing, 210009, China, 86 13776689750.ORCID 0009-0007-0755-2691 Liang ChenThe Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, No. 42, Baiziting, Nanjing, 210009, China, 86 13776689750.ORCID 0009-0008-2587-7120 Rongmin GuThe Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, No. 42, Baiziting, Nanjing, 210009, China, 86 13776689750.ORCID 0009-0004-9727-272X Huanqiu ChenThe Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, No. 42, Baiziting, Nanjing, 210009, China, 86 13776689750.ORCID 0009-0007-7600-8286 Xuezhi MingThe Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, No. 42, Baiziting, Nanjing, 210009, China, 86 13776689750.ORCID 0009-0002-6363-576X Xu WenThe Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, No. 42, Baiziting, Nanjing, 210009, China, 86 13776689750.ORCID 0009-0001-5281-5856 Weiguo XuThe Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, No. 42, Baiziting, Nanjing, 210009, China, 86 13776689750.ORCID 0009-0005-5579-747X Guangli SunThe Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, No. 42, Baiziting, Nanjing, 210009, China, 86 13776689750.ORCID 0009-0009-9419-1496 Hao FanThe Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, No. 42, Baiziting, Nanjing, 210009, China, 86 13776689750.ORCID 0000-0003-1039-4130 Zhe WangThe Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, No. 42, Baiziting, Nanjing, 210009, China, 86 13776689750.ORCID 0009-0006-8505-3495 Longhao YangThe Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, No. 42, Baiziting, Nanjing, 210009, China, 86 13776689750.ORCID 0009-0004-2145-7074 Gang Li *The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, No. 42, Baiziting, Nanjing, 210009, China, 86 13776689750.ORCID 0000-0002-7247-5289 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Background: Tunnel anastomosis is a novel anastomotic technique for digestive tract reconstruction following proximal gastrectomy. A previous retrospective study by our team demonstrated its favorable antireflux effect; therefore, we hypothesize that tunnel anastomosis is noninferior to double-tract jejunal interposition reconstruction in preventing postoperative reflux esophagitis, and we will conduct this prospective study to further validate this assumption. Objective: In this study, we will prospectively compare tunnel anastomosis with the currently more prevalent double-tract jejunal interposition reconstruction technique to further validate its safety and efficacy. Methods: This is a multicenter prospective randomized controlled study that will enroll 240 patients who will undergo proximal gastrectomy. The study will be divided into 2 groups: the tunnel anastomosis group and the double-tract jejunal interposition reconstruction group, with 120 patients in each group. Patients will undergo clinical assessments and complete questionnaires preoperatively, as well as at the 3rd, 6th, and 12th months postoperatively. The primary end point is the incidence of reflux esophagitis within 1 year. The secondary end points include perioperative safety, postoperative quality of life, and postoperative nutritional status. Results: Recruitment of patients commenced in March 2022 and is scheduled to conclude in February 2027. The follow-up for all enrolled patients will be completed by February 2028. Conclusions: To our knowledge, this is the first prospective study on this technique, aiming to provide novel insights into the methods of digestive reconstruction following proximal gastrectomy.
Indexed as
Anastomosis, SurgicalGastrectomyJejunumPlastic Surgery ProceduresEsophagitis, PepticFemaleHumansMaleMiddle AgedMulticenter Studies as TopicPostoperative ComplicationsProspective StudiesQuality of LifeRandomized Controlled Trials as Topicantirefluxdouble-tract jejunal interposition reconstructiongastric cancerproximal gastrectomytunnel anastomosis
Identifiers
PMID41894519
PMCPMC13026419
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390